<DOC>
	<DOCNO>NCT02853123</DOCNO>
	<brief_summary>The primary objective present study evaluate effect tiotropium + olodaterol fix dose combination ( FDC ) compare tiotropium monotherapy intensity breathlessness 3min constant speed shuttle test ( CSST ) . A secondary objective explore relationship reduction breathlessness 3min CSST reduction breathlessness activity everyday living measure dyspnea domain Chronic Respiratory Questionnaire ( CRQ ) follow bronchodilator therapy .</brief_summary>
	<brief_title>Effect Tiotropium + Olodaterol Breathlessness COPD Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Dyspnea</mesh_term>
	<mesh_term>Olodaterol</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Inclusion criterion : Patients must sign informed consent consistent International Conference Harmonization Good Clinical Practice guideline prior participation trial , include medication washout restriction Diagnosis Chronic Obstructive Pulmonary Disease relatively stable airway obstruction : post bronchodilator 30 % &lt; = Forced Expiratory Volume 1st second ( FEV1 ) &lt; 80 % predict normal ( European Coal Steel Community ) post bronchodilator FEV1/Forced Vital Capacity &lt; 0.70 visit 1 Male female patient &gt; =40 = &lt; 75 year age day sign consent . Current exsmokers smoke history &gt; 10 packyears . Patients never smoke cigarette must exclude . Baseline Dyspnea Index score &lt; 8 visit 0 . Hyperinflation rest , define Functional Residual Capacity &gt; 120 % predict visit 1 . Borg dyspnea score &gt; =4 end 3min Constant Speed Shuttle Test visit 2 Perform technically acceptable pulmonary function test ( spirometry body plethysmography ) complete multiple shuttle test study period Inhale medication competent manner Respimat® inhaler meter dose inhaler Exclusion criterion : Significant disease Chronic Obstructive Pulmonary Disease ( COPD ) ; significant disease , investigator 's opinion , may ( ) put patient risk ( ii ) influence study result ( iii ) cause concern regard patient 's ability participate Clinically relevant abnormal baseline haematology , blood chemistry , investigator 's opinion , creatinine &gt; x2 Upper Limit Normal exclude regardless clinical condition Current document diagnosis asthma COPD exacerbation 6 week prior screen Diagnosis thyrotoxicosis History myocardial infarction within 6 month screen Lifethreatening cardiac arrhythmia ( investigator judgment ) Known active tuberculosis Any malignancy unless free disease least 5 year ( treat basal cell carcinoma squamous cell skin cancer allow ) History cystic fibrosis Clinically relevant bronchiectasis ( investigator judgment ) Severe emphysema require endobronchial intervention within 6 month prior screen History significant alcohol drug abuse ( investigator judgment ) Any contraindication exercise test Patients undergone thoracotomy pulmonary resection Treatment oral patch ßadrenergics Treatment oral corticosteroid medication unstable dos dose excess equivalent 10 mg prednisone per day 20 mg every day Treatment antibiotic reason within 4 week screen Patients treated Phosphodiesterase Type 4 ( PDE4 ) inhibitor within 3 month screen visit enrol PDE4 inhibitor withdraw purpose enrol study Regular use daytime oxygen therapy &gt; 1 hour per day investigator 's opinion unable abstain use clinic visit Completion pulmonary rehabilitation program 6 week prior screen currently program Limitation exercise performance result factor fatigue exertional dyspnea , arthritis leg , angina pectoris , claudication , morbid obesity Endurance time &gt; =12 minute incremental shuttle walk test Oxygen saturation &lt; 85 % ( room air ) rest exercise . Taken investigational drug within 1 month 6 halflives case investigational drug class list within washout period specify prior screening visit Known hypersensitivity ßadrenergics and/or anticholinergic drug , Benzalkonium Chloride , Ethylenediaminetetraacetic acid component Respimat® inhalation solution Women pregnant , nursing , plan become pregnant trial Women childbearing potential use highly effective method birth control Previously randomize study currently participate another study Unable comply pulmonary medication restriction prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>